Biotech

Celldex Therapeutics announced the completion of patient enrollment in their Phase 2b METRIC study.

Celldex Therapeutics (NASDAQ:CLDX) announced the completion of patient enrollment in their Phase 2b METRIC study.
As quoted in the press release:

The Company’s Phase 2b METRIC study of glembatumumab vedotin in patients with metastatic triple negative breast cancers that overexpress gpNMB. Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, including breast cancer. Overexpression of gpNMB has been shown to promote the migration, invasion and metastasis of the disease. It is highly expressed in triple negative breast cancers, where it is associated with increased risk of recurrence and poor clinical outcome.

“We are extremely grateful to the METRIC investigators and the patients and families who supported this trial,” said Anthony Marucci, Co-Founder, President and Chief Executive Officer of Celldex Therapeutics. “Patients with triple negative breast cancer have very limited treatment options. We believe glemba holds significant promise as a potential new targeted treatment for patients with this devastating disease and look forward to topline data, likely in the second quarter of 2018.”

Click here to read the full press release.

Source: globenewswire.com

Featured

MARKETS

Markets
TSX19890.06-109.63
TSXV711.19-8.62
DOW32160.74-84.96
S&P 5004001.05+9.81
NASD11737.67+114.42
ASX7051.20-69.50

COMMODITIES

Commodities
Gold1838.71+5.34
Silver21.49+0.23
Copper4.21+0.06
Palladium2077.47+40.47
Platinum976.50+13.50
Oil101.46+1.70
Heating Oil3.74+0.06
Natural Gas7.40+0.02

DOWNLOAD FREE REPORTS

×